Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Commentary: Will vaccine fatigue affect how many people get the bivalent booster?

Pfizer’s and Moderna’s bivalent boosters, which are now available to many age groups, offer protection against the original COVID-19 virus plus the BA.4 and BA.5 omicron subvariants. Is the nation ready for yet another COVID-19 vaccine shot?

Chicago Tribune

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Benzinga

Is the new omicron vaccine worth it?

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Salon

Commentary: Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

Tribune News Service

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

EU Regulator Backs Pfizer's BA.4/5-Adapted COVID Booster

The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant. The latest recommendation is for a so-called bivalent vaccine developed by Pfizer and BioNTech, which targets BA.4/5 as well…

Asharq Al-Awsat

EU regulator clears Pfizer-BioNTech's tweaked COVID booster

The European Medicines Agency has recommended the authorization of a tweaked booster dose of the Pfizer-BioNTech coronavirus vaccine that includes protection against two of the latest versions of omicron, as countries look to bolster their immunization programs ahead of winter

The Independent UK

Covid-19 boosters: Immunologists answer 5 key questions about the new shots

What is different about the updated booster shots? Two scientists offer their expertise to answer five questions about the shots.

Inverse

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Benzinga

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.

Benzinga

Zenara launches generic version of Pfizer Covid drug Paxlovid

Sets MRP at ₹5,200 for a box of 20 Nirmatrelvir tablets, 10 tablets of Ritonavir

The Hindu

Get booster shots, doctors warn, as Australia all but declares COVID-19 dead

As social protections are abandoned, only 71.6 per cent of Australians aged 16 years and over have had their latest COVID vaccine booster.

The New Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

COVID rebound symptoms, positive tests after Paxlovid are more common than reported, study says

Resurgence of COVID-19 symptoms in patients treated with Pfizer Inc.’s Paxlovid appeared far more common than has been reported, and rebounding patients still risked spreading the disease, doctors said in a report on a series of cases in a top medical journal.

Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Chicago Sun-Times

No, COVID-19 isn’t winding down, scientists say, predicting it’ll be around the rest of our lives

Even with new boosters, experts predict the scourge that’s already lasted longer than the 1918 flu pandemic will linger far into the future. Here’s why.

Benzinga

Pfizer Whale Trades For September 07

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 11 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Los Angeles Times

Potential to mix up omicron booster with conventional vaccine raises concerns

Experts are voicing concerns about the potential for vaccine providers to mix up the omicron booster vial with those used for conventional vaccines.

Mic

It looks like we’ll be getting a COVID vaccine every year soon

America is trying a “new approach,” Biden said.

Bangkok Post

Govt to procure updated jabs

The Public Health Ministry is planning to procure second-generation Covid-19 vaccines in about a month.

Asharq Al-Awsat

Is COVID-19 Winding Down? Scientists Say No.

Is the coronavirus on its way out? You might think so. New, updated booster shots are being rolled out to better protect against the variants circulating now. The US Centers for Disease Control and Prevention has dropped COVID-19 quarantine and distancing recommendations. And more people have thrown off their masks…

Manchester Evening News

Covid-19 autumn booster jabs - who is eligible, when you can get them and how to book

Millions will be able to book an appointment to get the Covid booster jab

Daily Mirror

When will Omicron boosters be available? Who is eligible for Covid jab and how to book

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a second Coronavirus booster vaccine to target the Omicron variant ahead of the autumn booster programme

WEKU

Omicron boosters: Do I need one, and if so, when?

Updated COVID boosters are now available for anyone age 12 or older. The CDC is urging anyone who is eligible to sign up but some vaccine experts say some people might want to wait.

1 … 35 36 37 38

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Public Health Ministry

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.